FDA Announces 2024 NYTS Data and PATH Webinar

Regulations by 2FIRSTS.ai
Dec.19.2024
FDA Announces 2024 NYTS Data and PATH Webinar
FDA releases 2024 NYTS data showing record low youth tobacco use, PATH webinar announcement. Join now for important findings.

On December 18th, the Food and Drug Administration (FDA) released the 2024 NYTS data research results and announced an upcoming webinar for the PATH (Population Assessment of Tobacco and Health) network.

 

Teen Tobacco Product Usage Rates are at Their Lowest Level in 25 Years, but Disparities still Exist

 

The use of tobacco products among middle and high school students in the United States has dropped to its lowest level in 25 years, according to data released by the 2024 National Youth Tobacco Survey (NYTS). In the past year alone, at least 500,000 fewer students are using tobacco products.

 

In 2024, approximately 2.25 million middle and high school students reported using at least one tobacco product in the past 30 days, compared to 2.8 million in 2023. A significant decrease in e-cigarette use is the main factor for this decline, with 2.13 million adolescents using e-cigarettes in 2023 compared to 1.63 million in 2024. Cigarette use also reached its lowest level in survey history, with only 1.4% of students reporting current use in 2024.

 

Progress varies among different groups. Between 2023 and 2024, there was a significant decrease in the use of tobacco products, e-cigarettes, and various tobacco products among female students. Hispanic students also showed a downward trend during the same period. However, among non-Hispanic American Indian or Alaska Native students, the use of various tobacco products has increased, and non-Hispanic white students have also seen an increase in the use of nicotine pouches.

 

PATH Study: Release of the 7th Wave of PATH Study Biomarker Data File

 

The Food and Drug Administration's Center for Tobacco Products and the National Institute on Drug Abuse, a subsidiary of the National Institutes of Health, have released the seventh wave of the Biomarker Restricted Use Files (BRUF) collected between January 2022 and April 2023. Researchers can apply to access this data. This is the first time the seventh wave of biomarker data files has been included.

 

The first wave of sample data was also expanded to include adults who had previously experimented with or used tobacco products long-term.

 

FDA is Set to Hold a Large-scale Online Seminar on PATH Study

 

On January 9, 2025, the FDA will discuss key findings from the Population Assessment of Tobacco and Health (PATH) study in a web seminar. Over the past decade, this longitudinal study has tracked significant changes in tobacco product use, including the sharp increase and decrease in e-cigarette use, the emergence of new products such as nicotine pouches, and the growing concern about the concurrent use of multiple tobacco products. The seminar will provide an overview of the PATH study, highlighting how the scientific evidence it has generated guides FDA regulatory activities and public health efforts.

 

In recent comments and public meetings, leaders of the NIH and FDA have called for innovative smoking cessation treatments.

 

Leaders from the FDA and NIH have published a new commentary in the Annals of Internal Medicine, calling for innovative approaches in the development of smoking cessation treatments. The article emphasizes the need for active participation in smoking cessation research from stakeholders including clinicians, academia, industry, public health, and patient advocacy groups. Discussions and recommendations are made to promote research and development of smoking cessation therapies, with a focus on studying the long-term health effects of e-cigarettes and their toxicology. Furthermore, the FDA and NIH held a public meeting in October titled "Advancing Tobacco Cessation: Priorities for FDA and NIH," which focused on the development of innovative smoking cessation products to assist both adults and youth. The public comment period has been extended until December 20, 2024, allowing the public to share insights, data, and recommendations on advancing innovative smoking cessation products and therapies to help youth and adults.

 

FDA Issues Regulatory Science Policy Memorandum Related to Pre-market Application Review

 

In November of this year, the FDA released additional regulatory science policy memoranda related to premarket application reviews by the agency. This release included 13 memoranda from 2020 to 2023, outlining processes and prioritization methods for filing and reviewing premarket tobacco product applications (PMTAs) for flavored e-cigarettes and other products, as well as the basis for specific actions supporting environmental assessments. These scientific policy memoranda provide the FDA's views on specific topics at particular points in time, which may be updated due to policy changes.

 

In April, the FDA resumed the release of regulatory science policy memoranda. This is the fourth batch of memoranda released in 2024, including the one released today, bringing the total number of memoranda released by the FDA to 26.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Product | Japan Tobacco Expands Nordic Spirit Nicotine Pouch Range to Eight SKUs in Japan, Launches Melon Variant and Broadens Mint Retail Distribution
Product | Japan Tobacco Expands Nordic Spirit Nicotine Pouch Range to Eight SKUs in Japan, Launches Melon Variant and Broadens Mint Retail Distribution
Japan Tobacco Inc. (JT) launched Nordic Spirit Rich Melon Medium through selected tobacco retailers in Japan on November 2, 2026, while expanding physical retail distribution for three existing mint products previously sold through the CLUB JT online store. The melon launch brings Nordic Spirit's Japanese portfolio to eight SKUs. All four products are manufactured in Sweden, contain a standard 14 pouches per can and retail for ¥500 including tax. Since introducing Nordic Spirit in Japan in March, JT has expanded the brand's product lineup and distribution through its online store, convenience stores and selected tobacco retailers.
product
Nov.04
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City's Department of Consumer and Worker Protection (DCWP) opened applications on November 2, 2026, for a lottery covering tobacco and electronic cigarette retail dealer licenses, with a deadline of 5 p.m. New York local time on November 30. According to the city's October 1 notice, 55 electronic cigarette retail license slots are available across 23 community districts, including 28 in Brooklyn, alongside 322 tobacco retail license slots across 41 districts. Businesses must enter the lottery and, if invited, complete licensing requirements within 65 days. New York City continues to restrict e-cigarette retail sales to tobacco-flavored or unflavored products, while city retail licenses do not replace FDA product marketing authorization.
Market
Nov.04
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
A September online survey commissioned by Japanese smoking-accessories company Lightec found that 49.5% of respondents would consider reducing tobacco use if prices rose further, while 25.1% would consider switching to cheaper brands and 14.5% would consider using or combining alternatives such as vapes and nicotine-free herbal sticks. Another 64.6% expressed some level of interest in such alternatives. The survey covered 1,088 respondents aged 20 to 70 and was conducted by a company that sells NICOLESS nicotine-free vaping and herbal-stick products, meaning its findings should not be treated as representative of Japan's smoking population.
DATA
Oct.12